Citations

Clear

4847 citation(s) found for "Tu, Eric".

Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial
Zehra, Anum , Deng, Yihong , Swarna, Kavya Sindhu, Herrin, Jeph, Polley, Eric C. , Neumiller, Joshua J. , Galindo, R, Umpierrez, Guillermo E. , Ross, Joseph S. , Brito, Juan P., Maron, Bradley A. , Mickelson, Mindy M. , McCoy, Rozalina G., Herrin, Jeph , Galindo, Rodolfo J. , Herrin, Jeph , Galindo, Rodolfo J , Montori, Victor M , Maron, Bradley A , Mickelson, Mindy M , McCoy, Rozalina Grubina , Umpierrez, Guillermo E. , Polley, Eric C , Ross, Joseph S , Deng, Yihong , Neumiller, Joshua J. , Zehra, Anum , Swarna, Kavya, Brito, Juan P. , Montori, Víctor M. , Borah, Bijan J. , McCoy, Rozalina G.

Mayo Clinic

Journal of the American Heart Association | May 14, 2026 | Volume: 15 | Issue: 10 | Pages: No page available

10.1161/jaha.125.046238 | PMID 42132163 Get It

Background SGLT2 (sodium‐glucose cotransporter 2) inhibitors reduce major adverse cardiovascular events (MACE) in type 2 diabetes. However, no direct comparison of individual SGLT2 inhibitor drugs has been conducted, particularly among adults with moderate cardiovascular risk who comprise most people with type 2 diabetes. Methods We used data for commercial, Medicare Advantage, and Medicare fee‐for‐service beneficiaries to emulate a target trial of adults (≥21 years) with type 2 diabetes and moderate cardiovascular risk who started canagliflozin, dapagliflozin, or empagliflozin between 2015 and 2020. We estimated propensity scores using the super learner ensemble method and incorporated them as inverse probability of treatment weights into Cox models, estimating risk of MACE, expanded MACE, and hyperglycemic and hypoglycemic crises through December 31, 2022. Results The weighted cohort, balanced on all baseline covariates, included 137 232 patients (mean age 65.7 years [SD, 8.1], 75.3% non‐Hispanic White, 57.0% male, 81.9% on metformin, 11.4% on glucagon‐like peptide‐1 receptor agonists) starting canagliflozin (N=42 877), dapagliflozin (N=17 871), or empagliflozin (N=7648). The risk of MACE was lower among patients starting empagliflozin versus canagliflozin (hazard ratio [HR], 0.92 [95% CI, 0.87–0.97]), driven by reduced risk of all‐cause mortality (HR, 0.86 [95% CI, 0.80–0.94]). There was no difference in MACE between empagliflozin versus dapagliflozin or dapagliflozin versus canagliflozin therapy. There was no difference in remaining outcomes between the three drugs. Conclusions The 3 most used SGLT2 inhibitor medications demonstrate similar effectiveness on cardiovascular outcomes among patients with type 2 diabetes at moderate cardiovascular risk, with differences between these drugs small in magnitude. Clinicians and health systems should prioritize enhancing access to these cardioprotective therapies.
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Tesfay, Mulu Z. , Cios, Aleksandra , Cheng, Zetao , Ferdous, Khandoker Usran, Shelton, Randal S., Mustafa, Bahaa , Elliott, Natalie , Simões, Camila , Miousse, Isabelle R. , Siegel, Eric R. , Govindarajan, Rang, Cannon, Martin J. , Fernández-Zapico, Martín E. , Elliott, Natalie , Raupach, Elizabeth A. , Chabu, Chiswili Yves , Cios, Aleksandra , Urbaniak, Alicja Joanna , Bauer, Michael , Post, Steven R. , Chamcheu, Jean Christopher , Grdzelishvili, Valery Z. , Basnakian, Alexei G. , Moaven, Omeed , Borad, Mitesh J. , Nagalo, Bolni Marius

Mayo Clinic

Journal for ImmunoTherapy of Cancer | May 12, 2026 | Volume: 14 | Issue: 5 | Pages: e013671

10.1136/jitc-2025-013671 | PMID 42120181 Get It

Background Pancreatic ductal adenocarcinoma (PDAC), the most common malignant type of pancreatic cancer, is characterized by a dense desmoplastic stroma, low neoantigen burden, and a highly immunosuppressive tumor microenvironment (TME). Methods We present a novel strategy harnessing acute transplant rejection mechanisms by employing a recombinant oncolytic rVMG vector engineered to express murine alloantigens H-2Kb (rVMG-H-2Kb) or H-2Kk (rVMG-H-2Kk), thereby inducing tumor-specific antigenic mismatch responses. Results In vitro, rVMG-H-2Kb and rVMG-H-2Kk exhibited strong replication and cytolytic activity while inducing cell surface expression of both H-2Kk and endogenous H-2Kb, in addition to upregulation of antigen presentation genes (β2-microglobulin, Tap1, and Tapbp). In two immunocompetent PDAC models, intratumoral and systemic delivery of rVMG-H-2Kb and rVMG-H-2Kk delayed tumor progression, with rVMG-H-2Kk conferring a survival advantage. Multiplex immunohistochemistry and immunophenotyping revealed substantial TME remodeling, marked by increased effector T-cell infiltration, regulatory T-cell depletion, and reduced fibrosis. Spatial transcriptomics further showed compartment-specific immune activation and epithelial metabolic reprogramming, corroborating with enhanced tumor immunogenicity. Despite these effects, rVMG-H-2Kk also induced compensatory immunosuppressive pathways, including upregulation of antiviral response genes and immune checkpoint receptors such as programmed death-ligand-2. Importantly, combination therapy with rVMG-H-2Kk and murine checkpoint blockade (anti-programmed cell death protein-1 and anti-cytotoxic T-lymphocyte-associated protein 4) drastically improved survival compared to checkpoint blockade alone. Strikingly, surviving mice resisted tumor rechallenge, indicating the establishment of durable antitumor memory. Conclusion These findings establish rVMG-mediated alloantigen delivery as a novel immunotherapeutic platform capable of converting immune-cold tumors into immune-hot, sensitizing tumors to immune checkpoint inhibitors, and establishing durable antitumor immunity in PDAC.
Sonographic Normal Values for Ulnar Nerve Cross-Sectional Area
Luetmer, Marianne T. , Sorenson, Eric J. , Laughlin, Ruple S. , Boon, Andrea J. , Meiling, James B.

Mayo Clinic

Journal of Clinical Neurophysiology | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/wnp.0000000000001265 | PMID 42117691 Get It

Purpose: Neuromuscular ultrasound, including cross-sectional area measurements, adds diagnostic value to the clinical and electrodiagnosis evaluation of ulnar neuropathy at the elbow. Previously published reference values for ulnar nerve size vary widely. Our objective was to establish age-specific reference values for ulnar nerve cross-sectional area at multiple sites in asymptomatic adults for our laboratory. Methods: Healthy adult subjects without neuromuscular symptoms or disease were recruited from our tertiary referral electromyogram laboratory and staff. Ulnar nerve cross-sectional area measurements were made in short axis at the wrist, forearm, cubital tunnel, retrocondylar groove, 2 cm proximal to the medial epicondyle, and mid-upper arm with the elbow flexed to 90°. Dynamic neuromuscular ultrasound evaluated for subluxation and dislocation at the medial epicondyle. Results were stratified by age group (younger than 40, 40–60, and older than 60 years) with at least 20 subjects per sex per group, as well as by sex, body mass index, and handedness. The upper limit of normal was established as two standard deviations above the mean. Results: One hundred forty-two subjects (ages 18–84, mean 47.7 years) were included. Cross-sectional area significantly increased with age at all sites except the wrist. Cross-sectional area cut-offs at the retrocondylar groove were 10.0, 10.9, and 11.4 mm 2 , respectively, by age group. Ratios comparing retrocondylar groove and cubital tunnel to arm and forearm were calculated. Thirty-two percent had subluxation or dislocation in at least one limb. Conclusions: Age-specific cross-sectional area cut-offs and ratios may facilitate a more nuanced interpretation and diagnostic value when used in conjunction with clinical and electrodiagnosis evaluation of ulnar neuropathy at the elbow.
Biochemical Recurrence Irradiation or Observation ( BRIO ) in patients with prostate cancer: protocol for a randomised control trial
Wei, Nancy, Phillips, Ryan M., Kwon, Eugene, Stish, B.J., Ehman, Eric C. , Lucien, Fabrice, O'Byrne, Jamie, Bobek, Olivia , Andrews, Jack R. , Boorjian, S., Orme, Jacob J., Sharma, Vidit, Wei, Nancy , Wei, Nancy , Stish, Brad J, Lucien, Fabrice , Bobek, Olivia , Lucien, Fabrice , Shi, Qian , Park, Sean S. , Orme, Jacob J. , Sharma, Vidit

Mayo Clinic

BJU International | May 12, 2026 | Volume: 138 | Issue: 3 | Pages: 403-408

10.1111/bju.70305 | PMID 42117295 Get It

Background The optimal management of biochemical recurrence (BCR) after radical prostatectomy (RP) remains controversial, particularly in the absence of clinical or radiographic evidence of disease. Salvage radiotherapy (SRT) remains standard of care, but it is unclear whether SRT benefits patients when modern imaging with a multiparametric magnetic resonance imaging (mpMRI) and prostate‐specific membrane antigen‐positron emission tomography/computed tomography (PSMA‐PET/CT) are negative for local recurrence. Retrospective data comparing SRT to observation for such patients is fraught with selection bias, underscoring the need for a prospective randomised controlled trial. Study Design and Methods The Biochemical Recurrence Irradiation or Observation (BRIO) is a randomised study under the DIVINE trial framework (NCT06378866) enrolling men with BCR (prostate‐specific antigen [PSA] level ≥0.2, up to 1.5 ng/mL) after RP with no radiographic evidence of recurrence on mpMRI and PSMA‐PET/CT. Major inclusion criteria include age ≥18 years, biochemically recurrent prostate cancer after RP with a PSA level between 0.2 and 1.5 ng/mL, and no local or metastatic recurrence on imaging. A total of 312 patients will be enrolled. Participants are randomised 1:1 to standard‐of‐care SRT followed by surveillance (Group A), or initial observation with subsequent image‐guided therapy at radiographic progression (Group B). Based on historical analysis, a total of 30 metastasis events provides 80% power to detect a significant improvement (hazard ratio 0.5 corresponding to a 5‐year metastasis‐free proportion of 80.7% in the control group and 89.8% in the experimental group with one‐sided type I error rate of 0.15). All participants undergo baseline blood collection to measure prostate cancer‐extracellular vesicles and cell‐free DNA for biomarker development. Participants are followed in a 16‐week cycle with serial PSA measurements, repeat imaging if PSA doubles, safety assessment, and patient‐reported outcomes. Endpoints The primary endpoint is distant recurrence‐free survival at 5‐years using a 12‐month landmark to mitigate bias arising from differing assessment schedules for patients receiving optional 6 months of androgen deprivation therapy. Key secondary outcomes include time to hormone therapy, quality of life measures, adverse effects, and novel blood and urine biomarkers. Conclusion The BRIO study will clarify the clinical benefit of immediate SRT vs observation with image‐guided intervention in mpMRI and PET‐negative BCR after RP.
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy
Investigators, The HCMR, Kolm, Paul, DiMarco, John P., Desai, M Y, Ho, Carolyn Y., Kwong, Raymond Y., Dolman, Sarahfaye , Nickens, Patrice Desvigne, GELLER, NANCY, Kim, Dong-Yun, Schulz-Menger, Jeanette, Friedrich, M G, Maron, Martin S., Appelbaum, Evan, Francis, Gary S., Greenberg, Barry, Jerosch-Herold, Michael, Piechnik, Stefan, Mahmod, Masliza, Jacoby, Daniel L., Baldassare, Lauren A., White, J, Helms, Adam S., Choudhury, Lubna , Michels, Michelle, Salerno, Michael , Heitner, Steven B., Masri, Ahmad, Prasad, Sanjay , Plein, S V E N, Madias, Christopher, Mahrholdt, Heiko , Bucciarelli-Ducci, C, Nightingale, Angus K. , Weinsaft, Jonathan W., McCann, Gerry P., Rossum, Albert van, Germans, Tjeerd , Williamson, Eric E. , Geske, Jeffrey B., Dawson, D, Mongeon, François‐Pierre , Olivotto, Iacopo, Crean, Andrew , Woo, Anna, Owens, Anjali T., Anderson, L , Biagini, Elena, Newby, David E., Andre, Florian, Berry, C, Kim, Bette, Larose, Eric, Abraham, Theodore P., Sherrid, Mark V., Gelfand, Eli V. , Nagueh, Sherif F. , Rimoldi, Ornella, Camici, Paolo, Elstein, Eleanor , Watkins, Hugh, Weintraub, William S., Neubauer, Stefan, Schulz‐Menger, Jeanette , Nightingale, Angus K , Dawson, Dana , Kramer, Christopher M. , Kolm, Paul , Desai, Milind Y. , Ho, Carolyn Y. , Kwong, Raymond Y.K. , Desvigne‐Nickens, Patrice , Kim, Dong-Yun, Friedrich, Matthias G. , Maron, Martin S. , Appelbaum, Evan A., Link, Mark S. , Greenberg, Barry, Jerosch‐Herold, Michael , Piechnik, Stefan Kazimierz , Mahmod, Masliza , Raman, Betty , Jacoby, Daniel Louis , Baldassarre, Lauren A. , White, James A. , Chiribiri, Amedeo , Helms, Adam S. , Michels, Michelle , Bradlow, William M. , Heitner, S B, Masri, Ahmad , Mohiddin, Saidi , Plein, Sven , Madias, Christopher A. , Bucciarelli‐Ducci, Chiara , Weinsaft, Jonathan W. , Kim, Han W. , McCann, Gerry P , Rossum, Albert C. van , Geske, Jeffrey B. , Flett, Andrew S. , Olivotto, Iacopo , Woo, Anna, Owens, Anjali , Sharma, Sanjay , Biagini, Elena , Newby, David E. , André, Florian , Berry, Colin , Larose, Éric , Abraham, Theodore P. , Hays, Allison G , Sherrid, Mark V. , Rimoldi, Ornella , Camici, Paolo G. , Autore, Camillo , Watkins, Hugh , Weintraub, William S. , Neubauer, Stefan

Mayo Clinic

JAMA | May 11, 2026 | Volume: 335 | Issue: 22 | Pages: 1959

10.1001/jama.2026.5633 | PMID 42113540 Get It

Importance Current risk prediction guidelines for hypertrophic cardiomyopathy predict only sudden cardiac death and are imperfect, leading to avoidable deaths and unnecessary implantable cardioverter defibrillators. Objective To combine prospectively collected clinical history, imaging, genetic, and biomarker data to improve risk prediction of adverse events in hypertrophic cardiomyopathy. Design, Setting, and Participants A total of 2750 patients with hypertrophic cardiomyopathy were prospectively enrolled in the registry-based study from 44 sites in North America and Europe with expertise in hypertrophic cardiomyopathy and cardiac magnetic resonance (CMR) imaging. Participants were enrolled from April 1, 2014, to April 7, 2017. Exposures Patients underwent a health history questionnaire, blood sampling for biomarkers and genotyping, and contrast-enhanced CMR. Patients were followed up yearly by telephone and through records review regarding event documentation. Main Outcomes and Measures The predefined composite adjudicated primary end point was time to first event for hypertrophic cardiomyopathy–related deaths; nonfatal sustained ventricular arrhythmias (VAs) requiring cardioversion or defibrillation; and left ventricular (LV) assist device implant or heart transplant. A secondary end point was a composite of sudden cardiac death and nonfatal VA events. The elastic-net method identified the most important predictors. Cox proportional hazards regression assessed associations with time to the first end point. Results Of the 2750 prospectively enrolled patients, 2698 (98%) had analyzable data after 9 were excluded because they had hypertrophic cardiomyopathy phenocopies and 43 withdrew. Of these remaining patients, 1919 (71%) were male, mean age was 50 years (SD, 11 years), and 423 (16%) were from underrepresented racial and minority groups. The mean follow-up was 6.9 years (SD, 2.1 years). The primary event model in 104 patients included LV scar as a percentage of LV mass by late gadolinium enhancement (LGE%; hazard ratio [HR], 1.86; 95% CI, 1.58-2.20; P < .001), LV mass index (HR, 1.09; 95% CI, 1.01-1.17; P = .03), LV end-systolic volume index (HR, 1.28; 95% CI, 1.12-1.46; P < .001 ), all per 10-unit increase, history of heart failure at study entry (HR, 2.89; 95% CI, 1.75-4.77; P < .001), and log N-terminal pro–B-type natriuretic peptide (NT-proBNP; HR, 1.41; 95% CI, 1.17-1.70; P < .001) level per log unit, (C index for all, 0.77). An LGE percentage of the LV mass of 9% or higher substantially increased the primary composite event rate ( P = .001). The secondary sudden cardiac death and VA risk factor model (in 69 patients) included LGE%, LV mass index, LV ejection fraction, and log(NT-proBNP) (C index, 0.76). Conclusions and Relevance These results provide prospective evidence for incorporating cardiac magnetic resonance and NT-proBNP in the evaluation of patients with hypertrophic cardiomyopathy. Trial Registration ClinicalTrials.gov Identifier: NCT01915615
Revisiting KIR restriction and CD94 expression in diagnostic criteria for NK–large granular lymphocytic leukemia
Otteson, Gregory E., Jevremovic, Dragan, Morice, William G. , Timm, Michael, Hsi, Eric D. , Olteanu, Horatiu , Shi, Min , Morice, William George , Timm, Michael M, Hsi, Eric D , Olteanu, Horatiu , Shi, Min , Seheult, Jansen N. , Jevremović, Dragan , Horna, Pedro

Mayo Clinic

Blood Advances | May 8, 2026 | Volume: 10 | Issue: 17 | Pages: 6043-6046

10.1182/bloodadvances.2026020572 | PMID 42102292 Get It

Monogenic and Polygenic Contributions to Cardiomyopathy and Heart Failure Across Diverse Populations
Pereira, Naveen, Tan, Jia W. , Dikilitas, Ozan , Figueiral, Marta , Tan-Arroyo, Jennifer , Olson, Rory, Srinivas, Akshatha, (227567), Yao Xiao, Venettozzi, Marcella, Vairo, Filippo Pinto e, Schaid, DJ, Klee, Eric W., Dikilitas, Ozan , Olson, Rory J. , Panwar, Deepak, Cao, Jenny , Srinivas, Akshatha, Klee, Eric W. , Tan, Jia Wen

Mayo Clinic

No container title available | May 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9581360/v1 Get It

Abstract Pathogenic variants in cardiomyopathy genes confer substantial disease risk, yet clinical penetrance varies widely. The population-level prevalence, age-specific penetrance, and the extent to which polygenic susceptibility modifies disease risk across diverse ancestries remain poorly defined. This population-based cohort study leveraged genome sequencing and linked electronic health record data from the All of Us Research Program (n=414,830). This study found that P/LP variants in cardiomyopathy-associated genes were present in 0.91% of participants (95% CI, 0.88%–0.94%), with similar prevalence across ancestry groups. Compared with non-carriers, variant carriers had significantly higher odds of all-cause heart failure (ACHF, OR, 2.58; 95% CI, 2.31–2.89), non-ischemic heart failure (NIHF, OR, 2.74; 95% CI, 2.42–3.10), and non-ischemic cardiomyopathy (NICM, OR, 4.99; 95% CI, 4.44–5.63). Among carriers, by age 50 years, 24.5% (95% CI, 14.5%–33.4%) developed ACHF, 17.2% (95% CI, 8.8%–24.8%) developed NIHF, and 30.1% (95% CI, 19.5%–40.2%) developed NICM. Higher polygenic risk for heart failure was independently associated with increased risk of ACHF (OR, 1.81; 95% CI, 1.74–1.89), NIHF (OR, 1.66; 95% CI, 1.58–1.75), and NICM (OR, 1.69; 95% CI, 1.59–1.80). Among carriers with elevated polygenic risk, odds of disease were substantially higher than among non-carriers at average polygenic risk (ACHF: OR, 4.71; 95% CI, 4.17–5.32; NIHF: OR, 4.56; 95% CI, 3.99–5.22; NICM: OR, 8.51; 95% CI, 7.44–9.73). Results showed that P/LP variants in cardiomyopathy genes were relatively common in this large, ancestrally diverse cohort, and conferred increased risk of cardiomyopathy and HF, with incomplete but clinically meaningful penetrance. Polygenic risk for HF independently and additively increased disease risk across ancestries. Integrating both may improve risk stratification and enable more precise, equitable care.
Clinical Utility of the Moving Valgus Stress Test and Milking Maneuver for Medial Ulnar Collateral Ligament Injuries of the Elbow
Sciascia, Aaron D. , Chalmers, Peter, Smith, Matthew V. , Griffith, Timothy B. , Erickson, Brandon, Freehill, Michael T., Safran, Marc, Hardaway, Austin, Azar, Frederick M., Brolin, Tyler, Spence, David, Jones, Grant, Freehill, Michael T. , Sciascia, Aaron , Camp, Christopher L. , Griffith, Timothy Bryan , Freehill, Michael T , Bowman, Eric N. , Chalmers, Peter N. , Wolf, Brian R. , Safran, Marc R. , Azar, Frederick M. , Brolin, Tyler J. , Spence, David D. , Cox, Charles L. , LeClere, Lance E. , Jones, Grant

Mayo Clinic

The American Journal of Sports Medicine | May 6, 2026 | Volume: 54 | Issue: 8 | Pages: 1993-2002

10.1177/03635465261439107 | PMID 42087694 Get It

Background: Several special tests for detecting medial ulnar collateral ligament (MUCL) injuries of the elbow have been described, but data on the clinical utility of these tests are limited. Purpose: To determine the clinical utility of selected elbow special tests to detect MUCL injuries in an athletic population. Study Design: Cross-sectional study; Level of evidence, 3. Methods: A total of 84 consecutive patients with sports-related elbow pain underwent a standardized clinical examination. Overall, 6 special tests (moving valgus stress test, static valgus stress test, modified valgus stress test, milking maneuver, pronation flexion resistance test, and temple/cheek press test) were performed. Sensitivity, specificity, accuracy, positive/negative predictive value, and positive/negative likelihood ratio (LR+ and LR–, respectively) were calculated for individual tests and combinations of tests to detect MUCL injuries. Higher values for the LR+ and lower values for the LR– represent stronger clinical utility. Results: For detecting MUCL injuries, the moving valgus stress test resulted in the highest sensitivity (98%) and accuracy (93%) with the lowest LR– (2%). The milking maneuver had the highest LR+ (5.1) with the second highest sensitivity (77%) and accuracy (79%). The pronation flexion resistance test and the temple/cheek press test had the lowest LR+ (1.5 and 1.8, respectively) and highest LR– (94% and 95%, respectively) in addition to the lowest sensitivity (16% and 9%, respectively) and accuracy (33% and 30%, respectively). No combination of tests resulted in increased clinical utility. Conclusion: The moving valgus stress test and milking maneuver demonstrated acceptable clinical utility in which the moving valgus stress test was better for ruling out MUCL injuries and the milking maneuver was better at ruling in MUCL injuries. There was no added value when combining the 2 tests together or with other maneuvers.
E-cigarette use in vehicles: factors associated with secondhand exposure and behaviour from a US young adult sample in 2024
Elizabeth, K. , Watkins, Joslynn A., Iskra, Madison L. , Koris, Kristiann , Graham, Amanda L. , Soule, Eric K. , Hair, Elizabeth C. , Do, Elizabeth K , Graham, Amanda L , Soule, Eric K , Hair, Elizabeth C , Cha, Sarah

Mayo Clinic

Tobacco Control | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: tc-2025-059919

10.1136/tc-2025-059919 | PMID 42086323 Get It

Background This study investigates factors associated with electronic cigarette (e-cigarette) use and secondhand exposure in vehicles among US youth and young adults. Methods Data were collected from an online panel survey of individuals (N=3482, aged 15–25 years) from July to December 2024. Analyses included those who reported using any tobacco product in the past 30 days and answered items measuring exposure to (N=2600) and/or use of e-cigarettes in vehicles (N=2366). Logistic regression models assessed predictors of e-cigarette use and exposure in vehicles, including demographic, psychosocial and tobacco use characteristics. Results Among all participants, 67.1% reported e-cigarette use in the past 30 days. Of those reporting current e-cigarette use (N=2336), 60.6% reported using their e-cigarette/vape while travelling by car in the past 30 days. Of those who answered the question measuring exposure to e-cigarette use in vehicles (N=2600), 69.3% reported being in a vehicle where someone was using e-cigarettes. Higher nicotine dependence and residence in small metro and non-metro areas were associated with greater odds of using e-cigarettes in vehicles. Just meeting basic expenses or meeting needs with a little left, household tobacco use and residence in small metro areas were associated with greater odds of secondhand e-cigarette exposure. Discussion Public health interventions should place a strong focus on education and increasing public awareness of the health consequences of e-cigarette use in vehicles to protect bystanders from secondhand e-cigarette exposure.
Decoding RELA-Related Disease: A Spectrum of Immune Dysregulation in a Large Global Cohort
Dileepan, Gayathri , Basu, PhD Amrita, Murray, MD Elizabeth, D’Astous-Gauthier, Katherine , Lawrence, Monica G. , Maltz, Ross, Paquin, Maxime, Saca, MD Luis F., Taxter, Alysha J. , Towers, Victoria, Wonnaparhown, Alex , Akoghlanian, Shoghik , PhD, Eric Allenspach, MD,, Alsulami, Saleh , Alsuweiti, Motasem O. , Ardalan, Kaveh , CHAN, R P, MSCE, Joyce Chang, MD,, Efron, Adi , Igel, Dr. med Lina, Nigrovic, Peter, Padem, Nurcicek , Rosenwasser, Natalie , Sanchez-Manubens, PhD Judith, Skrie, Victor, Zheng, S , Guo, Lily, D(ABMLI), Roshini Abraham, PhD,, Basu, Amrita, Murray, Elizabeth T., Chapdelaine, Hugo , Maltz, Ross , Peng, Xiao P. , Saca, Luis, Zimmerman, Ofer , Allenspach, Eric J , Broderick, Lori , Cebecauerová, Dita , Dedeoğlu, Fatma , Igel, Lina, Naesens, Leslie , Nigrovic, Peter Andrija , Ombrello, Amanda K. , Sivaraman, Vidya

Mayo Clinic

Journal of Human Immunity | May 1, 2026 | Volume: 2 | Issue: CIS2026 | Pages: No page available

10.70962/cis2026abstract.7 Get It

RELA-related disease is a rare, autosomal-dominant condition presenting with immune dysregulation and immunodeficiency. RELA encodes the p65 subunit, a component of the canonical NFκB pathway. The underlying pathogenesis, at least in part, involves impaired NFκB activation, increased susceptibility to TNFα-induced apoptosis, and hyperinflammation. To date, only a modest number of cases have been documented worldwide, and the full clinical and functional spectrum of disease remains incompletely defined. This study represents a large global cohort identified with RELA variants, comprising 40 patients from 30 institutions, expanding our previous report of a single large kindred (1). The clinical spectrum includes arthritis, mucocutaneous ulcers, uveitis, dermatitis, irritable bowel disease, recurrent infections, lymphopenia, hypogammaglobulinemia, recurrent fevers, and susceptibility to neoplasia. The patients represent 36 kindreds with 28 unique RELA variants, of which 15 are missense, 7 nonsense, and 6 frameshift variants. Fifteen are in the Rel homology domain, 7 in the transcriptional activation domain, and 6 in the C-terminal region proximal to TAD (Fig. 1). Functional studies assessed the canonical NFκB pathway in 27% of the cohort (n = 11; healthy controls = 40). Patient peripheral blood mononuclear cells (PBMCs) were used to quantify total and phosphorylated p65 (ph-p65, Ser529) by flow cytometry after stimulation with PMA (100 ng/ml) and ionomycin (1 uM). In 8 patients, we assessed the kinetics of IκBα degradation, required for p65 phosphorylation and nuclear translocation of p65/p50. All patients tested had decreased total p65, while 64% had decreased ph-p65 with altered phosphorylation kinetics. Nearly 45% had impaired IκBα degradation. One patient (P4) demonstrated increased IκBα degradation and ph-p65, while a related proband (P1) had decreased ph-p65. Additionally, P4 did not have the same mucocutaneous clinical phenotype as P1 despite sharing the same RELA variant. This could reflect the effect of other genetic modifiers, epigenetic, environmental, or stochastic variations, which could lead to variable expressivity and/or incomplete penetrance. All patients appeared to have haploinsufficiency, as none had normal levels of p65. This study expands the clinical and genetic spectrum of RELA-related disease and provides mechanistic insights into the impact of these variants on p65 phosphorylation and downstream function, resulting in variable expressivity. Figure 1. RelA protein structure. Represents unique variant locations and categories, key domains, and phosphorylation sites. Source: UniProt. Adapted from (2). BioRender.